In addition, siglec1, CD22, MAG, siglec6, siglec8 showed reduced expression levels while siglec7, siglec10 and siglec16 exhibited increased expression in AML patients with NPM1 mutation. This evidence concerns the gene CD22 and acute myeloid leukemia.